Chapter 3 Head-to-head comparison of composite and individual biomarkers to predict clinical benefit to PD-1 blockade in non-small cell lung cancer Karlijn Hummelink1,2, Vincent van der Noort3, Mirte Muller2, Robert D. Schouten2, Michel M. van den Heuvel2,4, Daniela S. Thommen5, Egbert F. Smit2,6, Gerrit A. Meijer1 and Kim Monkhorst1 1Department of Pathology, Division of Diagnostic Oncology, 2Department of Thoracic Oncology, Division of Medical Oncology, 3Department of Biometrics, Netherlands Cancer Institute, Amsterdam, The Netherlands, 4Current address: Department of Pulmonary Diseases, Radboud University Medical Center, Nijmegen, The Netherlands, 5Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands, 6Current address: Department of Pulmonary Diseases, Leiden University Medical Center, Leiden, The Netherlands. PLOS ONE, 2024
RkJQdWJsaXNoZXIy MTk4NDMw